Company Profile
Bright Uro, Inc. is a US-based manufacturer of wireless, catheter-free urodynamics systems, headquartered in Irvine, California, USA. Founded in 2021 by Derek Herrera, the company operates as an independent private entity, serving US urology and urogynecology markets with an exclusive technology license from Cleveland Clinic (developed in collaboration with the Department of Veterans Affairs, Case Western Reserve University, and Parker Hannifin Corporation).
Core Products ＆ Technologies
Glean Urodynamics System
• Glean Urodynamics System: FDA 510(k) cleared (April 2025) wireless, catheter-free ambulatory urodynamic analyzer quantifying pressure and flow characteristics of the lower urinary tract; performs uroflow, cystometrogram, urethral pressure profile, and micturition studies
• Glean Abdominal Sensor: FDA 510(k) cleared (May 7, 2026) multi-channel sensor expanding Glean to full wireless, catheter-free multi-channel urodynamics including abdominal and detrusor pressure measurement; first clinical cases expected Q3 2026
• Bluetooth-Enabled Pressure Sensor: Flexible silicone tube sensor curling into a coil shape upon insertion, wirelessly transmitting data to cloud-based clinician and patient apps
• Digital Uroflowmeter: Reusable meter measuring urinary flow and volume, synchronizing with the cloud platform for physician review
Market Position ＆ Certifications
Bright Uro holds an emerging innovator position in the US urodynamics diagnostics market, disrupting conventional catheter-based systems. Key strengths include:
• 5 years of US medtech innovation heritage since founding
• Regulatory first: First and only FDA-cleared wireless, catheter-free urodynamics platform capable of standard multi-channel studies
• Clinical validation: MUSE prospective study (32 patients) demonstrated 100% successful insertion, 97% easy removal rate, and zero serious adverse events; data published in J Endourol
• Patient preference: Eliminates urethral catheterization discomfort, enabling ambulatory real-life physiologic filling data capture
• Venture backing: $32M oversubscribed Series A (2024) led by Laborie Medical Technologies with UC Investments, Freepoint Capital, and Laurelin Investors
Corporate Timeline
2021 — Founded in Irvine, California, USA, by Derek Herrera
2022 — Launched with $6M seed financing and $2M NIH Phase II SBIR grant; secured exclusive Cleveland Clinic technology license
2023 — Closed $23M Series A led by Laborie Medical Technologies
2024 — Completed oversubscribed $32M Series A second closing
2025 — Glean Urodynamics System received FDA 510(k) clearance (April); Cleveland Clinic performed first commercial case (June)
2026 — Glean Abdominal Sensor received FDA 510(k) clearance (May 7), enabling full multi-channel wireless catheter-free urodynamics
Target Markets ＆ Applications
• Overactive Bladder (OAB): Glean cystometry and pressure-flow studies for OAB diagnosis and treatment planning
• Urinary Incontinence: Wireless ambulatory monitoring to determine the source of leaks without artificial office-setting voiding
• Benign Prostatic Hyperplasia (BPH): Uroflow and pressure-flow assessment for enlarged prostate-related voiding dysfunction
• Neurogenic Bladder: Longitudinal bladder pressure monitoring for neurological micturition disorders
• Urogynecology: Multi-channel urodynamics for pelvic floor dysfunction and female voiding disorders
Contact Information
Global Headquarters
Address: 3 Goddard, Irvine, CA 92618, USA
Telephone: 949.590.0555
Email: derek@brighturo.com
Website: brighturo.com / gleanuds.com
Corporate Status
Entity Type: Independent Private Company (No Parent Company)
Stock: Not Publicly Traded
